{"brief_title": "Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection", "brief_summary": "The purpose of this study is to determine the safety and anti-HBV activity of ACH-126, 443 (beta-L-Fd4C) in comparison to lamivudine or placebo in treatment naive adults with chronic Hepatitis B infection.", "detailed_description": "Evaluation of safety and antiviral activity of 3 dose levels of ACH-126, 443 vs. lamivudine and placebo over 12 weeks of treatment in the population described.", "condition": ["Hepatitis B, Chronic"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["ACH-126, 443 (beta-L-Fd4C)", "Lamivudine", "Placebo"], "criteria": "Inclusion Criteria: - Adults >= 18 years of age - Chronic HBV infection, known to be HbsAg positive >= 6 months - Plasma HBV DNA level >= 100,000 copies/mL - HBe-antigen positive - HIV negative - Basic hematologic and chemistry parameters within acceptable limits (defined in protocol - No need for excluded medications - Subjects of reproductive capability must utilize two approved forms of birth control, one of which must be barrier protection. Exclusion Criteria: - HIV infection - Hepatitis C co-infection - Concurrent systemic antiviral treatment - Previous antiviral treatment for HBV infection within 6 months prior to randomization or treatment with 3TC for more than 6 months at any time in the past - Previous therapy with agents with significant systemic myelosuppressive or cytotoxic potential within 3 months of study start or the expected need for such therapy at study start - Alcohol abuse - Pregnancy or breast-feeding - Inability to tolerate oral medication - AST>7.0 times the upper limit of normal - ALT>7.0 times the upper limit of normal - Any clinical condition or prior therapy that, in the Investigators opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements - Use of any investigational drug.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Treatment Naive Chronic Hepatitis B, Achillion", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis B", "Hepatitis B, Chronic", "Antiviral Agents", "Lamivudine"], "id": "NCT00034359"}